Reuters Market Eye - Shares in Lupin Ltd (LUPN.NS) slump 4 percent after earlier falling as much as 4.7 percent following the launch of rival Mylan Inc's (MYL.O) generic version of the cholesterol-lowering Tricor tablets.
Mylan Inc said in a statement on Friday its unit Mylan Pharmaceuticals Inc has shipped generic Tricor, or fenofibrate tablets, of 48 mg and 145 mg.
Mylan compete against Lupin, which also sells generic versions of Tricor.
"Mylan's launch of Tricor will result in higher competition and decline in Lupin's market share in a drug which has a market size of $1.2 billion," said Ranjit Kapadia, senior vice president at Centrum Broking.
(Reporting by Abhishek Vishnoi)
Trending On Reuters
The BSE Sensex posted its worst monthly fall in more than two years, raising concerns a strong rally that saw indexes surge in the fiscal year was waning due to concerns about stock valuations and a more gradual economic growth. Full Article